Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 14 de 14
Filtrar
1.
Transl Sci Rare Dis ; 5(3-4): 99-129, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34268067

RESUMO

BACKGROUND: Recent advances in medical care have increased life expectancy and improved the quality of life for people with Down syndrome (DS). These advances are the result of both pre-clinical and clinical research but much about DS is still poorly understood. In 2020, the NIH announced their plan to update their DS research plan and requested input from the scientific and advocacy community. OBJECTIVE: The National Down Syndrome Society (NDSS) and the LuMind IDSC Foundation worked together with scientific and medical experts to develop recommendations for the NIH research plan. METHODS: NDSS and LuMind IDSC assembled over 50 experts across multiple disciplines and organized them in eleven working groups focused on specific issues for people with DS. RESULTS: This review article summarizes the research gaps and recommendations that have the potential to improve the health and quality of life for people with DS within the next decade. CONCLUSIONS: This review highlights many of the scientific gaps that exist in DS research. Based on these gaps, a multidisciplinary group of DS experts has made recommendations to advance DS research. This paper may also aid policymakers and the DS community to build a comprehensive national DS research strategy.

2.
Toxicol Sci ; 162(1): 64-78, 2018 03 01.
Artigo em Inglês | MEDLINE | ID: mdl-29121352

RESUMO

Chronic arsenic exposure can result in adverse development effects including decreased intellectual function, reduced birth weight, and altered locomotor activity. Previous in vitro studies have shown that arsenic inhibits stem cell differentiation. MicroRNAs (miRNAs) are small noncoding RNAs that regulate multiple cellular processes including embryonic development and cell differentiation. The purpose of this study was to examine whether altered miRNA expression was a mechanism by which arsenic inhibited cellular differentiation. The pluripotent P19 mouse embryonal carcinoma cells were exposed to 0 or 0.5 µM sodium arsenite for 9 days during cell differentiation, and changes in miRNA expression was analyzed using microarrays. We found that the expression of several miRNAs important in cellular differentiation, such as miR-9 and miR-199 were decreased by 1.9- and 1.6-fold, respectively, following arsenic exposure, while miR-92a, miR-291a, and miR-709 were increased by 3-, 3.7-, and 1.6-fold, respectively. The members of the miR-466-669 cluster and its host gene, Scm-like with 4 Mbt domains 2 (Sfmbt2), were significantly induced by arsenic from 1.5- to 4-fold in a time-dependent manner. Multiple miRNA target prediction programs revealed that several neurogenic transcription factors appear to be targets of the cluster. When consensus anti-miRNAs targeting the miR-466-669 cluster were transfected into P19 cells, arsenic-exposed cells were able to more effectively differentiate. The consensus anti-miRNAs appeared to rescue the inhibitory effects of arsenic on cell differentiation due to an increased expression of NeuroD1. Taken together, we conclude that arsenic induces the miR-466-669 cluster, and that this induction acts to inhibit cellular differentiation in part due to a repression of NeuroD1.


Assuntos
Arsênio/toxicidade , Fatores de Transcrição Hélice-Alça-Hélice Básicos/genética , Diferenciação Celular/efeitos dos fármacos , Poluentes Ambientais/toxicidade , Expressão Gênica/efeitos dos fármacos , MicroRNAs/genética , Animais , Diferenciação Celular/genética , Células-Tronco de Carcinoma Embrionário , Camundongos , Família Multigênica
3.
Anat Rec (Hoboken) ; 300(11): 1981-1992, 2017 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-28710803

RESUMO

Cellular vaults are ubiquitous 13 mega Da multi-subunit ribonuceloprotein particles that may have a role in nucleocytoplasmic transport. Seventy percent of the vault's mass consists of a ≈100 kDa protein, the major vault protein (MVP). In humans, a drug resistance-associated protein, originally identified as lung resistance protein in metastatic lung cancer, was ultimately shown to be the previously described MVP. In this study, a partial MVP sequence was cloned from channel catfish. Recombinant MVP (rMVP) was used to generate a monoclonal antibody that recognizes full length protein in distantly related fish species, as well as mice. MVP is expressed in fish spleen, liver, anterior kidney, renal kidney, and gills, with a consistent expression in epithelial cells, macrophages, or endothelium at the interface of the tissue and environment or vasculature. We show that vaults are distributed throughout cells of fish lymphoid cells, with nuclear and plasma membrane aggregations in some cells. Protein expression studies were extended to liver neoplastic lesions in Atlantic killifish collected in situ at the Atlantic Wood USA-EPA superfund site on the southern branch of the Elizabeth River, VA. MVP is highly expressed in these lesions, with intense staining at the nuclear membrane, similar to what is known about MVP expression in human liver neoplasia. Additionally, MVP mRNA expression was quantified in channel catfish ovarian cell line following treatment with different classes of pharmacological agents. Notably, mRNA expression is induced by ethidium bromide, which damages DNA. Anat Rec, 2017. © 2017 Wiley Periodicals, Inc. Anat Rec, 300:1981-1992, 2017. © 2017 Wiley Periodicals, Inc.


Assuntos
Peixes-Gato/metabolismo , Neoplasias Hepáticas/patologia , RNA Mensageiro/metabolismo , Partículas de Ribonucleoproteínas em Forma de Abóbada/metabolismo , Animais , Peixes-Gato/anatomia & histologia , Linhagem Celular , Creosoto/toxicidade , Modelos Animais de Doenças , Etídio/farmacologia , Feminino , Fundulidae , Perfilação da Expressão Gênica , Humanos , Fígado/patologia , Neoplasias Hepáticas/induzido quimicamente , Camundongos , Camundongos Endogâmicos BALB C , Membrana Nuclear/patologia , Proteínas Recombinantes/imunologia , Análise de Sequência de DNA , Partículas de Ribonucleoproteínas em Forma de Abóbada/genética , Partículas de Ribonucleoproteínas em Forma de Abóbada/imunologia
4.
Aquat Toxicol ; 177: 74-85, 2016 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-27262937

RESUMO

Atlantic killifish, Fundulus heteroclitus, are adapted to creosote-based PAHs at the US EPA Superfund site known as Atlantic Wood (AW) on the southern branch of the Elizabeth River, VA USA. Subsequent to the discovery of the AW population in the early 1990s, these fish were shown to be recalcitrant to CYP1A induction by PAHs under experimental conditions, and even to the time of this study, killifish embryos collected from the AW site are resistant to developmental deformities typically associated with exposure to PAHs in reference fish. Historically, however, 90 +% of the adult killifish at this site have proliferative hepatic lesions including cancer of varying severity. Several PAHs at this site are known to be ligands for the aryl hydrocarbon receptor (AHR). In this study, AHR-related activities in AW fish collected between 2011 and 2013 were re-examined nearly 2 decades after first discovery. This study shows that CYP1A mRNA expression is three-fold higher in intestines of AW killifish compared to a reference population. Using immunohistochemistry, CYP1A staining in intestines was uniformly positive compared to negative staining in reference fish. Livers of AW killifish were examined by IHC to show that CYP1A and AHR2 protein expression reflect lesions-specific patterns, probably representing differences in intrinsic cellular physiology of the spectrum of proliferative lesions comprising the hepatocarcinogenic process. We also found that COX2 mRNA expression levels were higher in AW fish livers compared to those in the reference population, suggesting a state of chronic inflammation. Overall, these findings suggest that adult AW fish are responsive to AHR signaling, and do express CYP1A and AHR2 proteins in intestines at a level above what was observed in the reference population.


Assuntos
Creosoto/toxicidade , Fundulidae/fisiologia , Receptores de Hidrocarboneto Arílico/genética , Receptores de Hidrocarboneto Arílico/metabolismo , Animais , Hidrocarboneto de Aril Hidroxilases/genética , Hidrocarboneto de Aril Hidroxilases/metabolismo , Embrião não Mamífero/efeitos dos fármacos , Regulação da Expressão Gênica/efeitos dos fármacos , Intestinos/efeitos dos fármacos , Intestinos/enzimologia , Intestinos/fisiopatologia , Fígado/efeitos dos fármacos , Fígado/metabolismo , Hidrocarbonetos Policíclicos Aromáticos/toxicidade , Transdução de Sinais/efeitos dos fármacos , Poluentes Químicos da Água/toxicidade
5.
Alzheimers Dement ; 10(5 Suppl): S430-52, 2014 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-25341459

RESUMO

With increasing numbers of people with Alzheimer's and other dementias across the globe, many countries have developed national plans to deal with the resulting challenges. In the United States, the National Alzheimer's Project Act, signed into law in 2011, required the creation of such a plan with annual updates thereafter. Pursuant to this, the US Department of Health and Human Services (HHS) released the National Plan to Address Alzheimer's Disease in 2012, including an ambitious research goal of preventing and effectively treating Alzheimer's disease by 2025. To guide investments, activities, and the measurement of progress toward achieving this 2025 goal, in its first annual plan update (2013) HHS also incorporated into the plan a set of short, medium and long-term milestones. HHS further committed to updating these milestones on an ongoing basis to account for progress and setbacks, and emerging opportunities and obstacles. To assist HHS as it updates these milestones, the Alzheimer's Association convened a National Plan Milestone Workgroup consisting of scientific experts representing all areas of Alzheimer's and dementia research. The workgroup evaluated each milestone and made recommendations to ensure that they collectively constitute an adequate work plan for reaching the goal of preventing and effectively treating Alzheimer's by 2025. This report presents these Workgroup recommendations.


Assuntos
Doença de Alzheimer/prevenção & controle , Doença de Alzheimer/terapia , Política de Saúde , Doença de Alzheimer/epidemiologia , Doença de Alzheimer/fisiopatologia , Animais , Ontologias Biológicas , Biomarcadores/metabolismo , Descoberta de Drogas , Humanos , Seleção de Pacientes , Parcerias Público-Privadas , Pesquisa Translacional Biomédica/métodos , Estados Unidos , United States Dept. of Health and Human Services , Instituições Filantrópicas de Saúde
6.
J Appl Toxicol ; 33(8): 766-73, 2013 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-22522787

RESUMO

The multidrug resistance-associated protein1 (MRP1/ABCC1) is a member of the ABCC transporter subfamily that mediates the efflux of pharmaceuticals, xenobiotics and steroid hormones, typically as glutathione, glucuronide or sulfate conjugates. Since loss of one transporter can be compensated by increasing the expression of other transporters and conjugation enzymes, we sought to examine compensatory changes in phase I, II and III enzyme expression in extrahepatic tissues, including the kidney, lungs and small intestine of intact or castrated Mrp1(-/-) male mice. In the kidney, the expression of several P450s, sulfotransferase 1a1 (Sult), glucuronosyltransferases (Ugt) and Mrps2-4, were significantly changed owing to castration alone. The only time genotype mattered was between the castrated FVB and Mrp1 knockout mice. In contrast, expression of the Ugts, Sult 1a1 and Mrp3 in the lungs was significantly downregulated in the Mrp1 knockout mice, so based exclusively on genotype. In the small intestine, there were interactions between steroid hormone levels and genotype, as the expression differences were only found in mice lacking Mrp1, and were changed between intact and castrated animals. The mechanism behind this pattern of expression may be to due to Nrf2 regulation, as its expression mirrors that of the phase II and phase III enzymes. These results indicate that compensatory responses owing to the loss of Mrp1 vary dramatically, depending on the particular tissue. This information will aid in the understanding of how drug uptake, disposition and elimination can be influenced by both hormone status and the presence and magnitude of transporter expression.


Assuntos
Expressão Gênica , Intestino Delgado/metabolismo , Rim/metabolismo , Pulmão/metabolismo , Proteínas Associadas à Resistência a Múltiplos Medicamentos/genética , Proteínas Angiogênicas/genética , Proteínas Angiogênicas/metabolismo , Animais , Arilsulfotransferase/genética , Arilsulfotransferase/metabolismo , Castração , Glucuronosiltransferase/genética , Glucuronosiltransferase/metabolismo , Glutationa/metabolismo , Hormônios Esteroides Gonadais/metabolismo , Inativação Metabólica , Masculino , Camundongos , Camundongos Knockout , Proteínas Associadas à Resistência a Múltiplos Medicamentos/metabolismo , Fator 2 Relacionado a NF-E2/genética , Fator 2 Relacionado a NF-E2/metabolismo , Xenobióticos/metabolismo
7.
Alzheimers Dement ; 7(6): 615-21, 2011 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-22055978

RESUMO

As the world's population ages, countries must prepare for the significant impact Alzheimer's disease will have on their health systems, their economies, and their citizens. In anticipation of major global demographic changes, many countries in the G-20 since 2000 have begun to develop and enact plans to address Alzheimer's disease as a national priority. However, even with nearly half of these participating countries having plans in place, there has been little research done to quantify the value of enacting a countrywide plan on this disease. In this review, we summarize recent national plans (from the year 2000 and beyond) and any results stemming from their respective recommendations and activities.


Assuntos
Doença de Alzheimer/prevenção & controle , Programas Nacionais de Saúde/organização & administração , Política Pública , Austrália , Canadá , China , União Europeia , França , Saúde Global , Humanos , Programas Nacionais de Saúde/legislação & jurisprudência , Política Pública/legislação & jurisprudência , República da Coreia , Reino Unido , Estados Unidos
8.
Toxicol Appl Pharmacol ; 250(2): 154-61, 2011 Jan 15.
Artigo em Inglês | MEDLINE | ID: mdl-20965206

RESUMO

Epidemiological studies have correlated arsenic exposure with cancer, skin diseases, and adverse developmental outcomes such as spontaneous abortions, neonatal mortality, low birth weight, and delays in the use of musculature. The current study used C2C12 mouse myoblast cells to examine whether low concentrations of arsenic could alter their differentiation into myotubes, indicating that arsenic can act as a developmental toxicant. Myoblast cells were exposed to 20 nM sodium arsenite, allowed to differentiate into myotubes, and expression of the muscle-specific transcription factor myogenin, along with the expression of tropomyosin, suppressor of cytokine signaling 3 (Socs3), prostaglandin I2 synthesis (Ptgis), and myocyte enhancer 2 (Mef2), was investigated using QPCR and immunofluorescence. Exposing C2C12 cells to 20 nM sodium arsenite delayed the differentiation process, as evidenced by a significant reduction in the number of multinucleated myotubes, a decrease in myogenin mRNA expression, and a decrease in the total number of nuclei expressing myogenin protein. The expression of mRNA involved in myotube formation, such as Ptgis and Mef2 mRNA, was also significantly reduced by 1.6-fold and 4-fold during differentiation. This was confirmed by immunofluorescence for Mef2, which showed a 2.6-fold reduction in nuclear translocation. Changes in methylation patterns in the promoter region of myogenin (-473 to +90) were examined by methylation-specific PCR and bisulfite genomic sequencing. Hypermethylated CpGs were found at -236 and -126 bp, whereas hypomethylated CpGs were found at -207 bp in arsenic-exposed cells. This study indicates that 20 nM sodium arsenite can alter myoblast differentiation by reducing the expression of the transcription factors myogenin and Mef2c, which is likely due to changes in promoter methylation patterns. The delay in muscle differentiation may lead to developmental abnormalities.


Assuntos
Arsenitos/toxicidade , Diferenciação Celular/efeitos dos fármacos , Metilação de DNA/efeitos dos fármacos , Mioblastos/efeitos dos fármacos , Miogenina/efeitos dos fármacos , Compostos de Sódio/toxicidade , Animais , Linhagem Celular , Imunofluorescência , Regulação da Expressão Gênica/efeitos dos fármacos , Fatores de Transcrição MEF2 , Camundongos , Fibras Musculares Esqueléticas/efeitos dos fármacos , Fibras Musculares Esqueléticas/metabolismo , Mioblastos/metabolismo , Fatores de Regulação Miogênica/efeitos dos fármacos , Fatores de Regulação Miogênica/genética , Miogenina/genética , Reação em Cadeia da Polimerase , Regiões Promotoras Genéticas/efeitos dos fármacos , RNA Mensageiro/metabolismo
9.
Alzheimers Dement ; 6(2): 89-97, 2010 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-20298968

RESUMO

Among the major impediments to the design of clinical trials for the prevention of Alzheimer's disease (AD), the most critical is the lack of validated biomarkers, assessment tools, and algorithms that would facilitate identification of asymptomatic individuals with elevated risk who might be recruited as study volunteers. Thus, the Leon Thal Symposium 2009 (LTS'09), on October 27-28, 2009 in Las Vegas, Nevada, was convened to explore strategies to surmount the barriers in designing a multisite, comparative study to evaluate and validate various approaches for detecting and selecting asymptomatic people at risk for cognitive disorders/dementia. The deliberations of LTS'09 included presentations and reviews of different approaches (algorithms, biomarkers, or measures) for identifying asymptomatic individuals at elevated risk for AD who would be candidates for longitudinal or prevention studies. The key nested recommendations of LTS'09 included: (1) establishment of a National Database for Longitudinal Studies as a shared research core resource; (2) launch of a large collaborative study that will compare multiple screening approaches and biomarkers to determine the best method for identifying asymptomatic people at risk for AD; (3) initiation of a Global Database that extends the concept of the National Database for Longitudinal Studies for longitudinal studies beyond the United States; and (4) development of an educational campaign that will address public misconceptions about AD and promote healthy brain aging.


Assuntos
Doença de Alzheimer/diagnóstico , Doença de Alzheimer/prevenção & controle , Bases de Dados como Assunto/normas , Cooperação Internacional/legislação & jurisprudência , Programas de Rastreamento/métodos , Sistema de Registros/normas , Doença de Alzheimer/terapia , Biomarcadores/análise , Ensaios Clínicos como Assunto/normas , Desenho de Fármacos , Educação em Saúde/normas , Humanos , Medição de Risco
10.
Gen Comp Endocrinol ; 167(1): 51-9, 2010 May 15.
Artigo em Inglês | MEDLINE | ID: mdl-20178799

RESUMO

The multidrug resistance-associated protein 1 (MRP1/ABCC1) is a member of the ABC active transporter family that can transport several steroid hormone conjugates, including 17beta-estradiol glucuronide, dehydroepiandrosterone sulfate (DHEAS), and estrone 3-sulfate. The present study investigated the role that MRP1 plays in maintaining proper hormone levels in the serum and testes. Serum and testicular steroid hormone levels were examined in both wild-type mice and Mrp1 null mice. Serum testosterone levels were reduced 5-fold in mice lacking Mrp1, while testicular androstenedione, testosterone, estradiol, and dehydroepiandrosterone (DHEA) were significantly reduced by 1.7- to 4.5-fold in Mrp1 knockout mice. Investigating the mechanisms responsible for the reduction in steroid hormones in Mrp1-/- mice revealed no differences in the expression or activity of enzymes that inactivate steroids, the sulfotransferases or glucuronosyltransferases. However, steroid biosynthetic enzyme levels in the testes were altered. Cyp17 protein levels were increased by 1.6-fold, while Cyp17 activity using progesterone as a substrate was also increased by 1.4- to 2.0-fold in mice lacking Mrp1. Additionally, the ratio of 17beta-hydroxysteroid dehydrogenase to 3beta-hydroxysteroid dehydrogenase, and steroidogenic factor 1 to 3beta-hydroxysteroid dehydrogenase were significantly increased in the testes of Mrp1-/- mice. These results indicate that Mrp1-/- mice have lowered steroid hormones levels, and suggests that upregulation of steroid biosynthetic enzymes may be an attempt to maintain proper steroid hormone homeostasis.


Assuntos
17-Hidroxiesteroide Desidrogenases/metabolismo , Androstenodiona/sangue , Proteínas Associadas à Resistência a Múltiplos Medicamentos/metabolismo , Testículo/metabolismo , Testosterona/sangue , 17-Hidroxiesteroide Desidrogenases/genética , Androstenodiona/metabolismo , Animais , Desidroepiandrosterona/sangue , Desidroepiandrosterona/metabolismo , Estradiol/sangue , Estradiol/metabolismo , Immunoblotting , Masculino , Camundongos , Camundongos Knockout , Proteínas Associadas à Resistência a Múltiplos Medicamentos/genética , Reação em Cadeia da Polimerase , Testosterona/metabolismo
11.
Alzheimers Dement ; 5(2): 85-92, 2009 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-19328434

RESUMO

This document proposes an array of recommendations for a National Plan of Action to accelerate the discovery and development of therapies to delay or prevent the onset of disabling symptoms of Alzheimer's disease. A number of key scientific and public-policy needs identified in this document will be incorporated by the Alzheimer Study Group into a broader National Alzheimer's Strategic Plan, which will be presented to the 111th Congress and the Obama administration in March 2009. The Alzheimer's Strategic Plan is expected to include additional recommendations for governance, family support, healthcare, and delivery of social services.


Assuntos
Doença de Alzheimer/fisiopatologia , Doença de Alzheimer/terapia , Ensaios Clínicos como Assunto/normas , Política de Saúde/legislação & jurisprudência , Programas Nacionais de Saúde/normas , Academias e Institutos , Idoso , Doença de Alzheimer/diagnóstico , Ensaios Clínicos como Assunto/economia , Ensaios Clínicos como Assunto/legislação & jurisprudência , Desenho de Fármacos , Indústria Farmacêutica/economia , Indústria Farmacêutica/legislação & jurisprudência , Indústria Farmacêutica/normas , Governo Federal , Política de Saúde/economia , Política de Saúde/tendências , Humanos , Comunicação Interdisciplinar , Programas Nacionais de Saúde/economia , Programas Nacionais de Saúde/legislação & jurisprudência , Avaliação de Resultados em Cuidados de Saúde , Sistema de Registros/normas , Projetos de Pesquisa , Estados Unidos
12.
Mol Pharmacol ; 68(1): 160-8, 2005 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-15814571

RESUMO

Multidrug resistance protein 3 (MRP3) is an ATP-binding cassette transporter that is able to confer resistance to anticancer agents such as etoposide and to transport lipophilic anions such as bile acids and glucuronides. These capabilities, along with the induction of the MRP3 protein on hepatocyte sinusoidal membranes in cholestasis and the expression of MRP3 in enterocytes, have led to the hypotheses that MRP3 may function in the body to protect normal tissues from etoposide, to protect cholestatic hepatocytes from endobiotics, and to facilitate bile-acid reclamation from the gut. To elucidate the role of Mrp3 in these processes, the Mrp3 gene (Abcc3) was disrupted by homologous recombination. Homozygous null animals were healthy and physically indistinguishable from wild-type mice. Mrp3(-/-) mice did not exhibit enhanced lethality to etoposide phosphate, although an analysis of transfected human embryonic kidney 293 cells indicated that the potency of murine Mrp3 toward etoposide ( approximately 2.0- to 2.5-fold) is comparable with that of human MRP3. After induction of cholestasis by bile duct ligation, Mrp3(-/-) mice had 1.5-fold higher levels of liver bile acids and 3.1-fold lower levels of serum bilirubin glucuronide compared with ligated wild-type mice, whereas significant differences were not observed between the respective sham-operated mice. Bile acid excretion, pool size, and fractional turnover rates were similar in Mrp3(-/-) and wild-type mice. We conclude that Mrp3 functions as an alternative route for the export of bile acids and glucuronides from cholestatic hepatocytes, that the pump does not play a major role in the enterohepatic circulation of bile acids and that the lack of chemosensitivity is probably attributable to functional redundancy with other pumps.


Assuntos
Etoposídeo/análogos & derivados , Proteínas Associadas à Resistência a Múltiplos Medicamentos/fisiologia , Animais , Ácidos e Sais Biliares/metabolismo , Linhagem Celular , Relação Dose-Resposta a Droga , Etoposídeo/farmacologia , Feminino , Inativação Gênica , Humanos , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Proteínas Associadas à Resistência a Múltiplos Medicamentos/biossíntese , Proteínas Associadas à Resistência a Múltiplos Medicamentos/deficiência , Proteínas Associadas à Resistência a Múltiplos Medicamentos/genética , Compostos Organofosforados/farmacologia , Gravidez
13.
Mar Environ Res ; 54(3-5): 379-83, 2002.
Artigo em Inglês | MEDLINE | ID: mdl-12420700

RESUMO

A heart fatty acid-binding protein (H-FABP) cDNA was isolated from the liver of the mummichog (Fundulus heteroclitus) and the complete cDNA sequence and predicted amino acid sequence was determined. This cDNA binds to a mRNA product of 0.95 kb with the highest level of RNA expression in the male liver, gills, and gonads. Exposure of mummichogs to the polycyclic aromatic hydrocarbon (PAH) pyrene significantly down-regulated H-FABP expression at the highest concentration. This study provides evidence that environmentally relevant toxicants can modulate H-FABP expression.


Assuntos
Proteínas de Transporte/biossíntese , Proteínas de Transporte/genética , DNA Complementar/genética , Fundulidae/fisiologia , Regulação da Expressão Gênica , Proteínas de Neoplasias , Hidrocarbonetos Policíclicos Aromáticos/efeitos adversos , Sequência de Aminoácidos , Animais , Sequência de Bases , Clonagem Molecular , Exposição Ambiental , Proteínas de Ligação a Ácido Graxo , Brânquias/química , Gônadas/química , Fígado/química , Masculino , Dados de Sequência Molecular , RNA/biossíntese
14.
Estados Unidos; National Multiple Sclerosis Society; s.d. 24 p.
Monografia em Inglês | LILACS, Coleciona SUS | ID: biblio-936544
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA